What Are the Best Benchmarks for Measuring Prior Authorization Denial Performance in 2026?

The Short Answer to Prior Authorization Denial Benchmarks

There is no single national prior authorization denial benchmark that every health plan, clinic, hospital, or care network should use as a universal pass/fail standard. The most defensible approach is to benchmark a provider against its own historical performance, the payer-specific results documented in its contracts, and peer organizations with similar specialties, patient populations, and service locations. In 2026, prior authorization performance should be measured across several stages: submission quality, initial approval, peer-to-peer review, appeal success, turnaround time, staff effort, patient abandonment, and prevented denials. A low initial denial rate can be misleading if staff spend excessive time correcting submissions, while a high appeal reversal rate may indicate effective recovery rather than poor front-end performance.

Also worth reading: Can Clinic Prior Authorization Automation Reverse Denials Before They Reach Patients? · How Can AI Prior Authorization for Clinics Reduce Care Delays? · How Do Prior Authorization Pilot Metrics Reveal AI Impacts Across Medicare?

A useful operating target is not simply “lowest denials.” It is the lowest avoidable burden and revenue loss at an acceptable level of service. Clinics should track at least four normalized rates: initial denial rate, appeal reversal or approval rate, administrative denial rate, and total denial-related cost as a percentage of authorized revenue. Reporting each measure by payer, service category, facility, clinician, and authorization channel makes the figures actionable. Because plans classify denials differently, every organization also needs a documented taxonomy separating medical-necessity denials, information requests, administrative errors, duplicate authorizations, and authorization-not-required decisions.

For a practical dashboard, many organizations begin by warning when initial denials exceed their trailing 12-month payer baseline by 2 percentage points, or when a payer’s denial rate is at least 25% above the organization’s same-specialty median for three consecutive months. Those figures are management triggers, not external industry benchmarks. They should be calibrated against actual staffing capacity, contract economics, appeal deadlines, and the clinical urgency of the services involved. As of September 25, 2026, the evidence still supports internal and peer comparison more strongly than claims of a reliable national standard.

How Prior Authorization Denial Rates Should Actually Be Calculated

The denominator is the most important part of a prior authorization denial benchmark. A provider should decide whether the rate covers authorization requests submitted, unique patient-service requests, or authorization opportunities after payer rules have been applied. Using submitted requests can make the rate look better if staff repeatedly submit incomplete or duplicate requests, although the organization is still absorbing rework. A more transparent model can report both submitted-request denial rates and unique-request rates, then show the number of corrections and duplicate submissions separately.

A basic initial denial rate is calculated as initially denied authorization requests divided by all initial authorization requests submitted during the period. This must exclude requests that were pending at the period close, or identify them separately. Otherwise, a month with complex cases and slower payer processing can appear worse than a month with easy cases and faster decisions. Denominator rules should also address cancellations, requests withdrawn before determination, and services performed without a required authorization. Keeping these records in one measurement policy prevents departments from optimizing different versions of the same metric.

Appeal performance requires a different denominator. Appeal success is usually the number of overturned or newly approved denals divided by completed appeals, not by all denials. Organizations should also calculate appeal volume as appealed denials divided by all initial denials, because a high reversal rate based on only five appeals is less reliable than the same rate based on 500 appeals. Medical-necessity, administrative, and level-of-care denials should not be combined because the evidence, reviewer pathway, and likely corrective action differ.

Turnaround and workload measures need equally precise definitions. Time to initial decision can be measured from the first complete submission, the first submission, or the payer’s receipt date, and each definition changes the result. For care coordination, a more useful measure may pair elapsed calendar time with staff touches, follow-up calls, records sent, and days until the patient received a final answer. This prevents automation or outsourcing from appearing beneficial merely because work was displaced rather than removed.

## Why National Benchmarks Are Not Reliable Enough for Operating Targets

The supplied research points to an important limitation: prior authorization metrics are revealing more about insurer practices, but material data gaps remain. KFF’s analysis should not be converted into a claim that every payer denies a fixed percentage of requests or that one organization is “below industry average” without matching the underlying definitions. Published studies may use different claims, surveys, authorization records, service categories, and methods of identifying denials. A benchmark drawn from hospital data may also be inappropriate for ambulatory clinics because hospitals treat different services, possess different documentation resources, and contract under different risk arrangements.

Payer variation is substantial. A health plan may use a different prior authorization rule for the same CPT code based on diagnosis, place of service, drug dose, delegated medical group, or benefit design. A denial attributed to a medical policy is not comparable with a missing fax header, a provider directory error, or a requirement that was never applicable. Plans can also change portals, clinical criteria, review vendors, and authorization channels during a measurement year. A static annual industry number can therefore describe the past without explaining current performance.

Peer groups offer more value than a broad national average. For clinic and care-network comparisons, a strong peer group should share the same specialty, geography, payer mix, authorization channel, and service intensity. Organizations should use rolling 12-month data and show both mean and median because a few very large systems can distort averages. Minimum sample sizes are necessary; for operational dashboards, a minimum of 30 completed authorization decisions is a reasonable floor for directional comparison, while 100 or more is preferable for stable rates. Small samples should be labeled rather than used to rank individual clinicians or sites.

The 25% increase in hospitals’ net revenue leakage attributed to denied claims, reported in the supplied Healthcare Finance News research context, should be treated as evidence that denial exposure can be material rather than as a universal multiplier. Its relevance to a clinic depends on revenue concentration, payer contracts, appeal success, and the proportion of denials that were never rebilled. A network with lower denied dollars may have a more serious problem if unresolved denials accumulate against timely filing limits or delay clinically important treatment. The correct benchmark is adjusted for the organization’s volume and economics.

Recommended Benchmarks for Clinics and Care Networks

The recommended primary benchmark is a rolling 12-month payer-specific baseline, recalculated quarterly and adjusted only when there is a documented operational or policy change. Alongside it, managers should maintain a network-wide target by service line and a peer benchmark against comparable organizations. Initial denial, appeal volume, appeal success, administrative denial, and time to final decision should each have an internal target, but no single measure should be rewarded in isolation. A balanced scorecard discourages teams from avoiding difficult cases, underappealing, or delaying submission until a deadline is nearly missed.

One practical model sets improvement bands around baseline. Green can mean performance at or better than the payer baseline, amber can indicate deterioration of 2 to 5 percentage points or a 25% relative increase, and red can indicate deterioration above 5 percentage points or 50% relative to baseline. These are proposed management thresholds, not published federal or industry standards. Sustained deterioration for two or three months is generally more informative than one unusual period, unless the cases involve urgent clinical services, statutory appeal deadlines, or unusually high financial exposure.

A second benchmark should address staff burden because the research context identifies staffing and denials as leading revenue-cycle stress points in 2026. Teams can measure touches per request, follow-up calls per request, minutes spent obtaining documentation, and unresolved authorization work per care coordinator. Targets should reflect complexity: a home-health authorization with extensive documentation should not be expected to consume the same staff time as a routine advanced-imaging request. A network might set an administrative goal of reducing avoidable touches by 10% in a quarter while keeping median turnaround below its payer-specific baseline.

A third benchmark is patient impact. Track abandonment before treatment, days from request to final decision, and cases in which the prescribed service was delayed, substituted, or canceled. These measures prevent a clinic from claiming success simply because denials were appealed efficiently. Care coordination software should preserve a traceable record of status changes, payer contacts, clinical documentation, notifications, and the final outcome. It should also show where patients or providers waited for information. Privacy, consent, role-based access, and audit logging are necessary because operational convenience does not remove obligations concerning protected health information.

Comparing Internal, Payer, Peer, and National Benchmarks

There are four common benchmark options, and each answers a different management question. Internal historical comparison is the strongest option for detecting deterioration because the organization controls definitions and can segment the data. Payer-specific comparison helps identify whether a problem is concentrated in a plan’s policy, portal, reviewer behavior, or network configuration. Peer comparison is useful for finding processes that perform better, but only after case mix and data definitions have been normalized. National data can provide context, but it should not be used as the sole basis for staffing, financial goals, or contractual decisions without evidence that the sample is comparable.

Vendor comparisons require particular caution. athenahealth’s announcement of more than 80 AI-native revenue-cycle features, as referenced in the supplied research, describes product capability rather than proof that every customer will reduce denial rates by a stated amount. Software features may automate status checks, document collection, or eligibility checks, but results still depend on payer connections, clinical evidence, staffing, contract terms, and deployment quality. A hospital-oriented tool also may not fit a clinic’s volume, workflow, or budget. Buyers should request customer-level before-and-after results, denominator definitions, implementation scope, and an explanation of whether the reported gain came from fewer denials, faster appeals, or simply reclassification.

The safest comparison method is cohort matching. Select organizations with similar authorization volumes, specialty mix, geography, and payer shares, then compare median initial denial rate, appeal success, 90th-percentile turnaround time, and administrative touches. Where possible, test differences rather than assuming they are meaningful. A three-percentage-point movement may be operationally important in a narrow service line but statistically uncertain when only 20 requests are involved. A national source should be labeled as descriptive if its population, timeframe, and calculation method are not available.

Practical Steps to Build a Defensible Benchmark Program

The first step is to establish a governed data dictionary before selecting a target. Definitions should cover what counts as an authorization request, duplicate, correction, initial denial, appeal, reversal, pending case, and final resolution. Assign one operational owner for payer rules, one for data quality, and one for clinical or utilization-review interpretation. This reduces the common problem where registration, revenue cycle, utilization management, and care coordination each report different denial totals. Historical data should be restated when definitions change so that a methodology correction is not presented as an improvement.

The second step is to create a 12-month baseline using complete and incomplete months as disclosed fields. Break results down by payer, service line, location, authorization method, and denial reason, while applying minimum sample thresholds. Establish an alert when a measure is 25% above its baseline and when it involves either high dollars, long delays, or clinical urgency. The third step is to run a small root-cause review each month. The review should distinguish missing information, mismatched codes, changed payer policy, incorrect portal routing, noncoverage, medical necessity, and failure to meet appeal requirements.

The fourth step is to connect authorization outcomes to staffing and financial performance. A 20% reduction in calls is not a success if median decision time rises by eight days. A $500,000 gross denial balance is not a $500,000 loss if $400,000 is recovered before timely filing limits and the remaining balance is immaterial, while a much smaller denial balance can be serious if a deadline is approaching. Report gross exposure, expected recovery, actual recovery, write-off timing, and patient-impact measures separately. These measures should feed a quarterly payer review and operational improvement plan rather than individual punitive ranking.

Common Mistakes When Comparing Denial Performance

The most common mistake is treating an authorization denial as equivalent to an adjudicated claim denial. Authorization can be denied even when the service is ultimately payable, and a paid claim can later be denied for coding, coverage, coordination-of-benefits, or documentation reasons. Mixing the two inflates the apparent authorization problem. Another mistake is counting a request every time it is faxed or resubmitted, which can create duplicate denials and make staff appear less effective. Each unique request should retain its complete submission and correction history.

Organizations also make the error of using raw counts instead of rates. A high-volume imaging center will almost always have more denials in dollars than a small specialty clinic, even if its denial rate is lower. Conversely, a small network can have a volatile rate based on a handful of decisions. Comparisons should be weighted carefully: dollar exposure may be weighted by billed amount, while workload should be weighted by complexity or staff time. It is not valid to assume that the highest denial rate deserves the most staff attention without considering service revenue and patient consequences.

Appeal strategy creates another source of distortion. Some teams appeal nearly every denial, producing a high approval rate but adding cost and delay; others appeal only obvious administrative errors, producing a lower percentage with little wasted effort. A sound program prioritizes cases by financial exposure, clinical urgency, reversibility, strength of clinical evidence, and deadline. Some denials should be corrected through a peer-to-peer discussion, while others require a formal appeal, a new request, or no additional action. The appropriate appeal rate depends on those factors, so “100% appeal success” is not automatically a desirable benchmark.

Finally, organizations should not attribute every adverse trend to insurer conduct without checking internal processes. Missing signatures, late records, wrong codes, duplicate submissions, and changes in payer portals can increase denials even when policy has not changed. Conversely, a payer may issue medically questionable denials or use criteria that differ from common practice. A balanced review tests both sides with timestamps, policy versions, complete records, and reproducible calculations. This is more useful than accepting either an uncritical vendor claim or an assumption that all denials are unavoidable.

Costs, Software Choices, and When to Act

Prior authorization denial management costs include staff time, payer calls, fax and portal fees where applicable, vendor services, data storage, appeals, delayed payment, and patient-care disruption. A clinic should calculate total operating cost rather than comparing subscription prices alone. A low-cost tool that adds 20 staff touches per request may be more expensive than a higher-priced platform that removes five touches and shortens the review cycle. Likewise, a broad enterprise platform may be excessive for a small clinic, while a point solution may not provide the auditability and cross-site reporting needed by a multi-state care network.

Pricing varies by module, authorization volume, number of users, integrations, implementation, and whether the vendor charges per request, per facility, or by enterprise agreement. The supplied research does not establish a reliable market-wide price range for prior authorization software, so clinics should request a written quote that separates implementation, recurring platform, integration, usage, and support fees. They should also ask for a pilot with a defined baseline and success measure, such as a 15% reduction in avoidable administrative touches without increasing median decision time. A pilot should use real payer scenarios and include the cost of clinician documentation, not only portal activity.

Act immediately when a denial threatens a statutory or contractual deadline, a time-sensitive treatment, or a large receivable. A structured escalation is also appropriate when the same payer exceeds its internal 25% relative-denial alert for three consecutive months, when appeal success falls more than 5 percentage points below baseline, or when the 90th-percentile decision time doubles. These are prudent operational triggers, but the organization should verify its payer rules, state requirements, and contract terms. Escalation should preserve evidence and deadline calculations before contacting a payer or choosing formal review.

The right software choice depends on operating maturity. A small clinic may begin with disciplined spreadsheets, a shared data dictionary, deadline alerts, and weekly denial review. A growing network benefits from electronic intake, status visibility, payer-specific queues, work queues, appeal timelines, and role-based reporting. A large organization may add predictive rules, cross-site capacity management, payer-policy monitoring, and integration with electronic health records and revenue-cycle systems. In every case, automation should support human review rather than automatically send unsupported clinical appeals or imply that artificial intelligence has determined medical necessity. The September 2026 supplier and staffing signals suggest pressure to modernize, but software is valuable only when it improves measurable decisions and preserves accountable review.

What a Useful 2026 Benchmark Report Should Contain

A credible report should state its measurement period, covered specialties, geography, payer mix, total requests, and inclusion rules. It should disclose pending cases, sample sizes, duplicates, and whether outcomes come from authorization systems, claims, appeals, or a combination. Rates should be presented with counts and dollars, and the report should show the denominator beside every percentage. Median and 90th-percentile time metrics are preferable to averages alone, particularly for urgent care and high-complexity requests.

The report should then explain whether changes reflect policy, payer mix, service volume, data completeness, or workflow. A useful executive page can summarize initial denial rate, appeal rate, appeal success, administrative denial rate, median days to decision, staff hours, gross denied dollars, recovered dollars, and patient delays. Each number should have a comparison to the same period last year, the trailing 12-month baseline, and an appropriate peer set where available. The report should label national references as context rather than standards whenever definitions are not aligned.

For getpulse.care, the strongest position is to help clinics and care networks establish trustworthy measurement, identify where coordination effort is being spent, and make patient-pulse and revenue-cycle signals visible without pretending that one number settles payer accountability. A product that provides denominator controls, denial-reason taxonomy, deadline alerts, role-based queues, and outcome reporting can support that work. It should not promise that software alone will eliminate denials or guarantee a fixed reduction. The durable value is a disciplined loop: measure the right unit, investigate the cause, assign accountable follow-up, and verify whether the change improved both administrative efficiency and patient access.